Immuron Spon Adr Each Repr 40 Ord Shs (IMRN) Stock
Immuron antibody developer for digestive and infectious conditions. Here's the price, business snapshot, and what's worth knowing about Immuron Spon Adr Each Repr 40 Ord Shs in October 2026.
Immuron Ltd (IMRN) is a small-cap biopharmaceutical company developing antibody-based products aimed mainly at enteric and infectious conditions. The company pursues a polyclonal antibody approach and advances programmes that may be used as oral or systemic prophylactics and therapeutics. For investors, key considerations are its early-stage pipeline, dependency on clinical and regulatory milestones and the need for ongoing funding — reflected in a market capitalisation of about $14.7m. Small-cap biotechs can offer meaningful upside around successful trials but carry heightened risks: clinical failures, regulatory delays, dilution from capital raises and limited trading liquidity. Before considering an investment, review the company’s latest financial reports, trial updates and regulatory filings, and assess your risk tolerance. This information is educational and not personal financial advice; returns are not guaranteed and the value of investments can fall as well as rise.
Immuron Spon Adr Each Repr 40 Ord Shs (IMRN) Stock Forecast
Analyst price target, next 12 months
$4.00
+267.0% vs today's $1.09
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Immuron Spon Adr Each Repr 40 Ord Shs have a consensus 12-month target of $4.00, above the current price of $1.09.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immuron's stock with a target price of $4, indicating strong growth potential.
Financial Health
Immuron Limited is showing solid revenue and profit margins, with healthy cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline catalysts
Clinical and regulatory milestones can shift market sentiment, but outcomes are uncertain and can cause significant volatility.
Technology focus
A polyclonal antibody approach targets infectious and gut conditions; technology may be differentiating but requires robust clinical proof.
Small-cap dynamics
With a market cap around $14.7m, shares may be thinly traded and sensitive to news; consider liquidity and funding risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.